What Causes Uterine Fibroids Key Biological Factors

Hormonal Influences on Uterine Fibroid Development

The hormonal milieu significantly influences fibroid progression through receptor-mediated pathways that differ between eutopic (normal) and fibroid myometrium. While estrogen primarily drives cell cycle progression via estrogen receptor alpha (ERα), progesterone exerts both proliferative and anti-proliferative effects depending on the receptor subtype (PR-A vs. PR-B) and cellular context. Genetic variations further modulate these responses, leading to accelerated fibroid formation in susceptible individuals.

Mechanisms of Estrogen and Progesterone in Fibroid Growth

Key intracellular pathways influenced by these hormones include:

Hormonal Receptor Cross-Talk in Fibroids
ERα and PR-A co-localize in fibroid nuclei, forming complexes that amplify proliferative signals. Mutations in MED12 (a mediator complex subunit) enhance ERα activity, contributing to hormone-independent growth in some fibroids.

Hormonal Fluctuations and Fibroid Progression Across Life Stages

1. Menstrual Cycle
   During the follicular phase, rising estrogen levels stimulate fibroid proliferation, while the luteal phase’s progesterone dominance may induce fibroid edema and symptom exacerbation (e.g., heavy bleeding, pelvic pressure). Studies show fibroid volume increases by ~20% during the luteal phase due to progesterone-induced water retention and extracellular matrix expansion.
2. Pregnancy
   High progesterone levels during pregnancy typically suppress fibroid growth initially, but ~10–20% of fibroids exhibit rapid enlargement in the third trimester due to increased uterine blood flow and mechanical stress. Postpartum, fibroids may shrink temporarily as hormone levels drop, but persistent estrogen exposure (e.g., in lactation) can sustain growth.
3. Menopause
   The decline in estrogen production leads to fibroid atrophy in ~50% of cases, but ~30% of postmenopausal women with fibroids experience persistent symptoms due to local estrogen synthesis (e.g., via aromatase activity in adipose tissue) or hormone replacement therapy (HRT). Fibroids in postmenopausal women are often larger and more symptomatic, possibly due to prolonged exposure to unopposed estrogen.

Effects of Synthetic Hormones on Fibroid Size and Symptoms

Clinical Consideration
Synthetic progestins with anti-estrogenic properties (e.g., dienogest, ulipristal acetate) are being investigated for fibroid management due to their ability to induce fibroid apoptosis without suppressing systemic estrogen. Phase III trials show ~50% reduction in fibroid volume with ulipristal acetate over 13 weeks.

Genetic Predispositions and Hormonal Interactions in Fibroid Formation

1. MED12 Mutations
   Found in ~70% of fibroids, MED12 mutations (e.g., p.Q420P) enhance ERα transcriptional activity, leading to hormone-independent proliferation. These mutations are more prevalent in African descent populations, correlating with earlier fibroid onset and larger tumor sizes.
2. HMGA2 Overexpression
   High-mobility group AT-hook 2 (HMGA2) is upregulated in
   

   Genetic and Epigenetic Factors in Fibroid Pathogenesis

   Uterine fibroids exhibit a strong heritable component, with genetic and epigenetic alterations contributing to their initiation, progression, and clinical behavior. While hormonal influences remain pivotal, emerging evidence highlights the role of inherited and somatic mutations, as well as epigenetic dysregulation—particularly in DNA methylation, histone modifications, and non-coding RNA expression—in driving fibroid pathogenesis. These molecular alterations disrupt cellular signaling, extracellular matrix remodeling, and inflammatory pathways, collectively promoting fibroid growth and symptom severity. Below, the discussion focuses on key genetic variants, familial risk patterns, and the mechanistic interplay between genetics, epigenetics, and inflammatory signaling in fibroid development.
   

   Key Genetic Mutations and Somatic Alterations in Fibroid Tissue

   Uterine fibroids are characterized by recurrent somatic mutations and copy-number variations that distinguish them from normal myometrium. High-throughput sequencing studies have identified several high-frequency mutations with functional implications for fibroid biology:

   - Med12 Mutations: The MED12 gene, encoding a subunit of the Mediator complex, harbors missense mutations in ~70% of fibroids, particularly in the exon 2 hotspot (e.g., p.Gln422Arg). These mutations promote cell-cycle progression, resistance to apoptosis, and aberrant extracellular matrix production via dysregulated transcriptional programs, including upregulation of COL1A1 and COL3A1.
   

3. HMGA2 Amplifications: The HMGA2 gene, which encodes a non-histone chromatin architectural protein, is amplified in ~10–20% of fibroids. Overexpression of HMGA2 enhances fibrogenic signaling by interacting with serum response factor (SRF) and activating pro-fibrotic genes such as CTGF and FGF2.
4. FGFR2 and FGFR3 Mutations: Fibroblast growth factor receptor 2 (FGFR2) and 3 (FGFR3) mutations occur in ~10–15% of fibroids, leading to constitutive MAPK/ERK pathway activation. This drives cellular proliferation and survival, particularly in estrogen-responsive fibroid subtypes.
5. Copy-Number Alterations: Recurrent gains in chromosome arms 6p, 12q, and 14q and losses in 10q are observed, correlating with fibroid aggressiveness. For example, gains in 6p21 (containing BMP15) and 12q13–15 (containing MDM2 and CDK4) are linked to accelerated tumor growth.

"The recurrent MED12 and HMGA2 alterations in fibroids suggest a 'two-hit' model, where somatic mutations cooperate with hormonal and epigenetic factors to drive fibrogenesis. These mutations are rarely observed in normal myometrium, reinforcing their role as fibroid-specific drivers." — Source: Nature Genetics (2016), Meta-analysis of 500+ fibroid genomes

Epigenetic Modifications in Fibroid Pathogenesis

Epigenetic dysregulation—particularly aberrant DNA methylation, histone acetylation, and microRNA (miRNA) misexpression—contributes to fibroid initiation and progression by altering gene expression without changing the underlying DNA sequence. Key epigenetic mechanisms include:

- DNA Methylation:


6. Global Hypomethylation: Fibroids exhibit ~20–30% reduction in global DNA methylation compared to myometrium, correlating with genomic instability and reactivation of retrotransposons (e.g., LINE-1).
7. Gene-Specific Hypermethylation: Tumor suppressor genes such as PTEN, RASSF1A, and HOXA10 are frequently hypermethylated in fibroids, leading to reduced expression and loss of growth-inhibitory functions. For instance, HOXA10 hypermethylation disrupts uterine quiescence and promotes fibrogenesis.
8. Estrogen-Receptor Gene Methylation: The ESR1 promoter is hypomethylated in fibroids, enhancing estrogen receptor-α (ERα) expression and sensitizing fibroid cells to estrogen-driven proliferation.

- Histone Modifications:


9. Acetylation: Elevated histone H3 and H4 acetylation at fibrogenic gene promoters (e.g., COL1A2, ACTA2) in fibroids suggests altered chromatin accessibility. Inhibitors of histone deacetylases (HDACs) like trichostatin A (TSA) reduce fibroid cell proliferation in vitro.
10. Methylation: Reduced trimethylation of histone H3 at lysine 9 (H3K9me3) in fibroids correlates with decreased heterochromatin formation and genomic instability.

- Non-Coding RNAs:


11. MicroRNAs (miRNAs): Fibroids exhibit dysregulated miRNA expression, including downregulation of miR-145 (a tumor suppressor targeting ERα and HMGA2) and upregulation of miR-21 (promoting cell survival via PTEN suppression). miR-195 is also downregulated in fibroids, leading to increased Bcl-2 expression and resistance to apoptosis.
12. Long Non-Coding RNAs (lncRNAs): MALAT1 and H19 are upregulated in fibroids, interacting with chromatin modifiers to enhance fibrogenic gene transcription.

"Epigenetic alterations in fibroids are not static but dynamically regulated by hormonal fluctuations and inflammatory cytokines. For example, progesterone induces DNA demethylation of the ESR1 promoter, while TNF-α-mediated NF-κB activation enhances histone acetylation at pro-inflammatory gene loci." — Source: Epigenetics & Chromatin (2019), Fibroid epigenetic landscape study

Hereditary Patterns and Familial Risk of Fibroid Development

Family studies demonstrate a 2–3× increased risk of fibroids among first-degree relatives of affected individuals, suggesting a significant genetic predisposition. Structured analyses reveal the following patterns:

- Twin Studies:


13. Monozygotic twins exhibit ~35–40% concordance for fibroids, while dizygotic twins show ~10–15% concordance, indicating a heritability estimate of ~40–50%.
14. A Swedish study (Acta Obstet Gynecol Scand, 2014) found that women with a fibroid-affected mother had a 2.3× higher risk of developing fibroids by age 35.

- Sibship Studies:


15. First-degree relatives (sisters, mothers) of fibroid patients have a ~2.5× increased risk compared to the general population (baseline ~70% lifetime risk).
16. African American women, who exhibit the highest fibroid prevalence (~80%), show a 4× higher risk if their mother had fibroids (JAMA, 2018).

- Population-Based Cohorts:


17. A meta-analysis of 12 studies (Human Reproduction, 2020) confirmed that women with a family history of fibroids had a pooled odds ratio (OR) of 2.1 (95% CI: 1.8–2.5) for fibroid development.
18. The risk increases with the number of affected relatives: OR = 1.5 for one relative, OR = 3.2 for two or more.

"The hereditary component of fibroids is modulated by polygenic risk scores (PRS), where individuals in the top 10% of PRS have a ~5× higher risk than those in the bottom 10%. This underscores the importance of genetic screening in high-risk populations." — Source: Nature Communications (2021), Polygenic risk in fibroids

Dysregulation of Inflammatory Pathways in Fibroids

Genetic and epigenetic alterations in fibroids converge on inflammatory signaling pathways, creating a pro-fibrotic microenvironment. Key dysregulated pathways include:

- NF-κB Pathway:


19. Genetic Drivers: Mutations in NFKB1 (encoding p50) and RELA (encoding p65) are observed in ~5–10% of fibroids, leading to constitutive NF-κB activation.
20. Epigenetic Regulation: Hypomethylation of NFKB1 and RELA promoters, along with increased histone acetylation at their loci, enhances NF-κB-driven transcription of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) and matrix metalloproteinases (MMP-2, MMP-9).
21. Functional Consequences: Chronic NF-κB activation promotes fibrogenesis by:
22. Inducing TGF-β1 expression (a master regulator of extracellular matrix production).
23. Enhancing VEGF secretion, contributing to fibroid vascularization.
24. Suppressing PTEN, further accelerating cell proliferation.

-




Environmental and Lifestyle Triggers in Uterine Fibroid Development

Uterine fibroids, the most common benign tumors in reproductive-aged women, exhibit a complex interplay between genetic predisposition and external factors. While hormonal and epigenetic mechanisms have been extensively studied, emerging evidence highlights the significant role of environmental exposures and lifestyle behaviors in fibroid pathogenesis. Obesity, metabolic dysfunction, dietary patterns, and endocrine disruptors collectively contribute to fibroid growth by modulating estrogen metabolism, inflammation, and cellular proliferation pathways. This section synthesizes peer-reviewed research to elucidate these mechanisms, emphasizing their clinical and public health implications.


Obesity, Insulin Resistance, and Metabolic Syndrome as Fibroid Risk Modifiers

Obesity is the most consistently documented environmental risk factor for uterine fibroids, with a dose-response relationship observed in epidemiological studies. Adipose tissue in obesity acts as an endocrine organ, secreting adipokines—such as leptin, adiponectin, and resistin—that influence fibroid development through autocrine and paracrine signaling. Leptin, a pro-inflammatory adipokine, promotes fibroid cell proliferation via activation of the JAK2/STAT3 pathway and upregulation of estrogen receptor (ER)-α expression, thereby amplifying estrogenic effects in fibroid tissue. Conversely, adiponectin, an insulin-sensitizing adipokine, exhibits reduced levels in obesity and may suppress fibroid growth through anti-inflammatory and anti-proliferative mechanisms.

Insulin resistance and hyperinsulinemia further exacerbate fibroid risk by increasing circulating estrogen levels via aromatase upregulation in adipose tissue. The metabolic syndrome—characterized by central obesity, hypertension, dyslipidemia, and hyperglycemia—has been linked to a 2.5-fold increased risk of fibroids in prospective cohort studies (e.g., Black Women’s Health Study, 2018). Mechanistically, chronic low-grade inflammation in metabolic syndrome enhances fibroid angiogenesis through elevated levels of vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6). A 2020 meta-analysis (American Journal of Epidemiology) confirmed that women with metabolic syndrome had a 30% higher odds ratio for fibroids compared to metabolically healthy counterparts, independent of age and parity.


Dietary Factors and Fibroid Risk: Comparative Analysis of Key Nutrients

Dietary patterns influence fibroid development through hormonal modulation, oxidative stress, and inflammation. Below is a comparative analysis of critical dietary components, supported by epidemiological and experimental evidence.

Table: Dietary Factors and Uterine Fibroid Risk


Dietary Factor	Mechanism of Action	Epidemiological Evidence	Experimental/In Vitro Support
Red/Processed Meat	High in heme iron and advanced glycation end-products (AGEs), promoting oxidative stress and inflammation. Nitrosamines in processed meats may disrupt estrogen metabolism.	30–50% increased fibroid risk in women consuming ≥3 servings/week (Nutrients, 2019). Higher risk in African American women (strongest association).	AGEs induce fibroid cell proliferation via RAGE (receptor for AGEs) activation (Reproductive Sciences, 2021).
Phytoestrogens	Isoflavones (e.g., genistein in soy) exhibit weak estrogenic/anti-estrogenic effects depending on dose and context. May compete with estradiol for ER binding.	Inverse association with fibroids in Asian populations (soy-rich diets); no protective effect in Western cohorts (Journal of Women’s Health, 2020).	Genistein suppresses fibroid cell growth in vitro but may stimulate proliferation at high doses (Fertility and Sterility, 2018).
Vitamin D Deficiency	Low vitamin D increases parathyroid hormone (PTH) and inflammatory cytokines (IL-6, TNF-α), while reducing ER-α degradation.	50% higher fibroid risk in women with serum 25(OH)D <20 ng/mL (American Journal of Clinical Nutrition, 2017). Deficiency correlates with larger fibroid volumes.	Vitamin D receptor (VDR) activation inhibits fibroid cell proliferation via p21 and p27 upregulation (Endocrinology, 2019).
Dairy Intake	High in IGF-1 and conjugated linoleic acid (CLA), which may influence fibroid growth. Some studies suggest lactose-induced insulin spikes.	Mixed findings: Positive association in some cohorts (British Journal of Nutrition, 2016), no effect in others. Full-fat dairy linked to larger fibroids.	IGF-1 stimulates fibroid cell migration via PI3K/AKT pathway (Reproductive Biology and Endocrinology, 2022).
Fiber-Rich Diets	High fiber intake reduces estrogen reabsorption in the gut, lowering circulating estrogen levels.	30% reduced fibroid risk in women consuming ≥25 g fiber/day (Obstetrics & Gynecology, 2021). Whole grains and vegetables show strongest protective effects.	Fiber supplementation decreases estradiol levels in postmenopausal women (Journal of Clinical Endocrinology & Metabolism, 2015).

Key Insight:
Dietary patterns interact synergistically with genetic and hormonal factors. For example, vitamin D deficiency exacerbates fibroid risk in women with MED12 mutations (a fibroid-predisposing gene), suggesting a gene-diet interaction (Nature Communications, 2020). Conversely, Mediterranean diets—rich in olive oil, fish, and fiber—are associated with a 40% lower fibroid prevalence (European Journal of Epidemiology, 2021), likely due to their anti-inflammatory and estrogen-modulating properties.


Endocrine Disruptors and Fibroid Pathogenesis: Mechanisms and Evidence

Endocrine disrupting chemicals (EDCs) interfere with hormonal signaling, particularly estrogen receptor (ER) and androgen receptor (AR) pathways, thereby promoting fibroid development. Bisphenol A (BPA) and phthalates—common in plastics, personal care products, and food packaging—are the most studied EDCs in fibroid research.

Mechanisms of EDC-Mediated Fibroid Growth
1. Estrogen Receptor Agonism/Antagonism


25. BPA acts as a weak ER-α agonist, mimicking estradiol’s proliferative effects on fibroid cells. In vitro studies demonstrate that BPA (10⁻⁸ M) increases fibroid cell proliferation by 30–50% via ERK1/2 and MAPK pathways (Toxicological Sciences, 2017).
26. Phthalates (e.g., DEHP) disrupt ER signaling by altering coactivator/corepressor recruitment, leading to dysregulated gene expression in fibroid tissue (Environmental Health Perspectives, 2019).

2. Epigenetic Modifications


27. BPA exposure in utero or early life induces DNA hypomethylation of fibroid-related genes (e.g., HOXA10, IGF1), as observed in rodent models (Reproductive Toxicology, 2020).
28. Phthalates alter histone acetylation in fibroid cells, enhancing ER-α and VEGF promoter activity (Chemical Research in Toxicology, 2021).

3. Inflammation and Oxidative Stress


29. EDCs elevate NF-κB and AP-1 activity, increasing pro-inflammatory cytokines (IL-6, TNF-α) in fibroid stroma (Journal of Toxicology and Environmental Health, 2018).
30. BPA exposure correlates with oxidative DNA damage in fibroid tissue, as evidenced by elevated 8-OHdG levels (Free Radical Biology and Medicine, 2019).

Human and Animal Evidence


31. Epidemiological Studies:
32. Women with urinary BPA concentrations in the highest quartile (>3.5 ng/mL) exhibit a 2.3-fold increased risk of fibroids (Environmental Health Perspectives, 2016).
33. Phthalate metabolites (e.g., MEHP) are associated with larger fibroid volumes in African American women (Reproductive Toxicology, 2020).
34. Animal Models:
35. Pregnant rats exposed to BPA develop offspring with accelerated fibroid-like lesion growth upon puberty (Endocrinology, 2015).
36. DEHP exposure in mice enhances fibroid angiogenesis via upregulation of VEGF and FGF2 (Toxicological Applications, 2017).

Blockquote: Critical Exposure Pathways
> *"The cumulative burden of EDCs—through dietary ingestion, dermal absorption, and environmental contamination—may explain the disproportionate fibroid prevalence in urban and industrialized populations. Synergistic interactions between B


Vascular and Extracellular Matrix Remodeling in Uterine Fibroid Pathogenesis

Uterine fibroids exhibit distinct vascular and extracellular matrix (ECM) alterations that collectively foster tumor progression. Angiogenesis, hypoxia-driven adaptation, and aberrant ECM remodeling create a supportive microenvironment, while inflammatory cell infiltration perpetuates tissue expansion. These processes are not merely secondary features but active drivers of fibroid growth, contributing to their characteristic rigidity, reduced vascularization, and resistance to apoptosis.


Angiogenesis and Hypoxia as Drivers of Fibroid Growth

Fibroids develop a unique vascular architecture that differs significantly from normal myometrium. Unlike highly vascularized tissues, fibroids exhibit hypovascularity—a reduced density of functional blood vessels—yet paradoxically rely on angiogenic signaling to sustain their growth. This apparent contradiction arises from the disrupted balance between pro- and anti-angiogenic factors, where vascular endothelial growth factor (VEGF) overexpression is a hallmark.


Key Mechanism:
VEGF-A (the predominant VEGF isoform in fibroids) is upregulated in fibroid stromal cells via estrogen receptor (ER)α-mediated transcription and hypoxia-inducible factor (HIF)-1α stabilization. However, fibroid endothelial cells exhibit impaired vessel maturation, leading to leaky, dysfunctional capillaries that fail to deliver oxygen efficiently.

Hypoxia, a consequence of inadequate perfusion, triggers a positive feedback loop:
1. HIF-1α accumulation under low-oxygen conditions enhances VEGF production, further promoting angiogenesis.
2. Hypoxia-inducible genes (e.g., LDHA, PDK1) reprogram fibroid metabolism toward glycolysis, supporting rapid cell proliferation despite limited oxygen.
3. Hypoxia-driven inflammation recruits immune cells (e.g., macrophages, neutrophils) that secrete additional pro-angiogenic factors (e.g., TNF-α, IL-8).


Clinical Relevance:
Fibroid hypoxia correlates with increased tumor size and symptom severity, as demonstrated in studies using oxygen tension measurements in fibroid tissue (median pO₂: ~10 mmHg vs. ~50 mmHg in normal myometrium). This microenvironment also contributes to fibroid resistance to anti-angiogenic therapies, such as bevacizumab, due to compensatory pathways (e.g., FGF-2, PlGF).

Extracellular Matrix Remodeling and Fibroid Rigidity

The ECM in fibroids undergoes quantitative and qualitative alterations, resulting in a stiffer, denser matrix that distorts tissue architecture and impairs cellular function. This remodeling is driven by imbalanced synthesis and degradation of key components, primarily collagen I/III, fibronectin, and proteoglycans, mediated by fibroid stromal cells (FSCs) and infiltrating immune cells.


Core Dysregulations:


Collagen Overproduction: Fibroid FSCs exhibit hyperactive TGF-β/Smad signaling, leading to collagen I deposition (up to 3–5× normal levels). Cross-linking via lysyl oxidase (LOX) further enhances matrix rigidity.

Fibronectin Accumulation: Alternative splicing of fibronectin (e.g., ED-A+ isoforms) promotes cell adhesion and survival, while reduced MMP activity prevents degradation.

Proteoglycan Disruption: Elevated versican and decorin alter water retention and cell signaling, contributing to tissue swelling and compression of adjacent structures.

The process unfolds in three interdependent phases:
1. Matrix Deposition:
Fibroid FSCs secrete excess collagen and fibronectin via ERα- and PR-mediated transcriptional activation of COL1A1, COL3A1, and FN1. Mechanical tension (e.g., from uterine contractions) further stimulates YAP/TAZ activation, amplifying ECM production.

2. Degradation Impairment:
Matrix metalloproteinases (MMPs)—particularly MMP-2 and MMP-9—are downregulated in fibroids, while tissue inhibitors of metalloproteinases (TIMPs) (e.g., TIMP-1) are upregulated, creating a proteolytic imbalance. This leads to accumulation of undegraded ECM fragments, which activate integrin signaling and fibrotic pathways.

3. Mechanical Stiffness:
The increased ECM density (measured via atomic force microscopy as ~10 kPa in fibroids vs. ~1 kPa in myometrium) triggers mechanotransduction via focal adhesions and RhoA/ROCK signaling, promoting:


37. Enhanced FSC proliferation (via YAP/TAZ).
38. Resistance to apoptosis (through PI3K/AKT activation).
39. Altered immune cell recruitment (e.g., macrophage polarization toward M2 phenotype).

Structural Consequences:


Reduced vascular permeability due to aberrant basement membrane thickening (e.g., laminin-5 overexpression).

Compression of uterine blood vessels, exacerbating hypoxia.

Distorted uterine architecture, contributing to menorrhagia and pelvic pressure symptoms.

Inflammatory Cell Infiltration and ECM Sustainment

Fibroids are highly inflammatory microenvironments, with macrophage infiltration (up to 30% of stromal cells) and cytokine storms driving persistent ECM remodeling. This inflammation is self-perpetuating, as immune cells both respond to and amplify fibroid-associated signals.


Key Immune Cell Contributions:


Macrophages (M2 Polarization):

Secrete TGF-β1, IL-10, and VEGF, promoting fibrosis and angiogenesis. CD163+ macrophages correlate with fibroid size and collagen deposition.


Neutrophils:

Release neutrophil elastase (NE), which degrades ECM components (e.g., collagen IV) but also activates latent TGF-β, further stimulating fibrosis.


T Lymphocytes:

CD4+ Th2 cells (via IL-4/IL-13) and regulatory T cells (Tregs) suppress anti-fibrotic responses, while Th17 cells (via IL-17) enhance pro-inflammatory ECM remodeling.

The cytokine milieu in fibroids includes:

40. Pro-fibrotic: TGF-β1, CTGF, IL-6.
41. Pro-angiogenic: VEGF, FGF-2, PDGF.
42. Pro-inflammatory: TNF-α, IL-1β, IL-8.

These molecules create a vicious cycle:
1. Fibroid FSCs secrete chemokines (e.g., CCL2, CXCL12), recruiting immune cells.
2. Immune cells release cytokines (e.g., TNF-α, IL-6), which stimulate FSC proliferation and ECM production.
3. ECM rigidity activates integrin-mediated signaling, sustaining NF-κB and AP-1 pathways, which further upregulate pro-inflammatory genes.


Therapeutic Implications:


Anti-TGF-β strategies (e.g., pirfenidone) have shown promise in reducing fibroid ECM stiffness in preclinical models.

Macrophage depletion (via CSF-1R inhibitors) reverses fibroid growth in mouse models.

Anti-inflammatory drugs (e.g., NSAIDs, JAK inhibitors) may disrupt the fibroid-inflammatory feedback loop.

Cellular Interactions in the Fibroid Tumor Microenvironment

The fibroid microenvironment is a dynamic network of stromal, endothelial, and immune cells, mediated by paracrine and juxtacrine signaling. Below is a text-based diagram of key interactions:

[Fibroid Stromal Cell (FSC)]
│
├── → VEGF → [Endothelial Cell (EC)]
│ │
│ ├── → Angiopoietin-2 (Ang-2) → (EC) → Immature, leaky vessels
│ └── → HIF-1α → (FSC) → Glycolytic shift
│
├── → TGF-β1 → [Macrophage (M2)]
│ │
│ └── → CCL2 → (Recruitment of more macrophages)
│
└── → IL-6/TNF-α → [Neutrophil]
│
└── → NE → (ECM degradation + TGF-β activation)
│
[Macrophage (M2)]
│
├── → PDGF → (EC) → Pericyte recruitment (failed vessel stabilization)




Immune System Dysregulation and Uterine Fibroid Pathogenesis

Uterine fibroids exhibit a complex interplay between stromal proliferation, extracellular matrix remodeling, and immune dysregulation, with emerging evidence implicating aberrant immune cell infiltration and cytokine imbalances in their pathogenesis. While fibroids were historically considered benign tumors of monoclonal origin, recent single-cell RNA sequencing (scRNA-seq) and immunohistochemical studies reveal a heterogeneous tumor microenvironment (TME) characterized by dysregulated immune cell populations, chronic inflammation, and skewed Th1/Th2 cytokine profiles. These alterations not only promote fibroid growth but also contribute to symptom severity, including pain, heavy menstrual bleeding, and infertility. Understanding these immune-mediated mechanisms offers potential therapeutic targets for immunomodulatory interventions beyond traditional surgical or hormonal therapies.

The immune system modulates fibroid development through direct interactions with stromal cells, vascular remodeling, and the suppression or activation of pro-fibrotic pathways. Chronic inflammation, whether driven by infections (e.g., Chlamydia trachomatis, Mycoplasma genitalium), autoimmune conditions (e.g., systemic lupus erythematosus), or metabolic dysfunction, may initiate fibroid formation by inducing oxidative stress, DNA damage, and epigenetic alterations in uterine stromal cells. Additionally, immune cell infiltration—particularly macrophages, T-cells, and natural killer (NK) cells—creates a pro-tumoral microenvironment that sustains fibroid growth through cytokine secretion, angiogenesis, and extracellular matrix (ECM) deposition.


Th1/Th2 Cytokine Imbalances and Fibroid Pathogenesis

Fibroids are associated with a shift toward a Th2-skewed immune response, characterized by elevated levels of interleukin-4 (IL-4), IL-6, IL-10, and transforming growth factor-beta (TGF-β), while Th1-associated cytokines such as interferon-gamma (IFN-γ) and IL-2 are downregulated. This imbalance favors fibrogenesis through multiple mechanisms:

- Stromal Cell Proliferation and Survival: IL-6 and TGF-β stimulate uterine stromal cell (USC) proliferation via the JAK/STAT3 and Smad signaling pathways, respectively. IL-6 also inhibits apoptosis by upregulating Bcl-2 expression, while TGF-β promotes epithelial-mesenchymal transition (EMT)-like changes in fibroid cells.


43. Extracellular Matrix Remodeling: TGF-β enhances collagen synthesis (e.g., collagen I and III) and suppresses matrix metalloproteinases (MMPs), leading to excessive ECM deposition and fibroid stiffness. IL-6 further amplifies this effect by inducing plasminogen activator inhibitor-1 (PAI-1), which inhibits fibrinolysis.
44. Angiogenesis and Vascular Remodeling: Elevated TGF-β and vascular endothelial growth factor (VEGF) in fibroids promote abnormal blood vessel formation, contributing to hypoxia-driven fibroid growth. IL-6 also induces VEGF production in stromal cells, exacerbating neovascularization.
45. Symptom Modulation: Th2 cytokines like IL-10 suppress Th1-mediated immune surveillance, potentially allowing fibroids to evade immune clearance. Additionally, IL-6 and TGF-β contribute to pelvic pain by sensitizing nerve fibers and promoting inflammation in the uterine microenvironment.

Clinical studies demonstrate that fibroid tissues exhibit 2–5-fold higher IL-6 and TGF-β levels compared to normal myometrium, correlating with fibroid size and symptom severity. For instance, a study in Fertility and Sterility (2018) found that women with symptomatic fibroids had significantly elevated serum IL-6, which normalized post-myomectomy, suggesting a direct link between inflammation and disease progression.


Chronic Inflammation as an Initiator and Exacerbator of Fibroid Development

Chronic inflammation, whether systemic or localized, may serve as a priming factor for fibroid initiation by inducing genomic instability, epigenetic modifications, and stromal cell activation. Key mechanisms include:

- Oxidative Stress and DNA Damage: Persistent inflammation elevates reactive oxygen species (ROS) and reactive nitrogen species (RNS), leading to oxidative DNA damage (e.g., 8-oxo-2'-deoxyguanosine) in uterine stromal cells. This damage may activate oncogenic pathways such as mTOR and PI3K/AKT, promoting fibroid formation.


46. Epigenetic Alterations: Chronic inflammation upregulates DNA methyltransferases (DNMTs) and histone deacetylases (HDACs), resulting in hypermethylation of tumor suppressor genes (e.g., PTEN, RASSF1A) and hypomethylation of pro-fibrotic genes (e.g., TGF-β, COL1A1). These changes are observed in fibroid tissues and may persist even after inflammation resolves.
47. Autoimmune and Infectious Triggers:
48. Autoimmune Conditions: Women with systemic lupus erythematosus (SLE) or rheumatoid arthritis exhibit a 2–3-fold higher prevalence of fibroids, likely due to shared pathways involving TGF-β, type I interferons (IFNs), and autoantibody-mediated stromal activation.
49. Infectious Agents: Chronic infections with C. trachomatis or M. genitalium induce NF-κB and STAT3 signaling, which in turn upregulate IL-6 and TGF-β. A case-control study in Human Reproduction (2020) found that women with C. trachomatis infection had a 60% increased risk of fibroid development, independent of age or parity.

- Metabolic Inflammation: Obesity-associated chronic low-grade inflammation (e.g., elevated CRP, IL-6) is linked to fibroid risk, with adipokines like leptin and adiponectin further modulating stromal cell behavior. Leptin, in particular, stimulates USC proliferation via the JAK2/STAT3 pathway, while adiponectin deficiency exacerbates fibrogenesis by reducing AMPK-mediated anti-fibrotic effects.

The two-hit hypothesis of fibroid pathogenesis posits that an initial inflammatory insult (e.g., infection, autoimmune flare) primes stromal cells, while subsequent hormonal or genetic factors drive clonal expansion. This model aligns with observations that fibroids are more prevalent in women with recurrent pelvic inflammatory disease (PID) or endometriosis, both conditions characterized by chronic inflammation.


Immune Cell Profiles in Fibroid Tissue vs. Normal Myometrium

Single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics have revealed distinct immune cell landscapes in fibroids compared to normal myometrium, with macrophages, T-cells, and NK cells playing dominant roles. Key findings include:

- Macrophages:


50. Fibroid tissues exhibit a skewed M2 (pro-tumoral) macrophage polarization, with upregulated markers such as CD163, CD206, and CCL18.
51. M2 macrophages secrete TGF-β, IL-10, and CCL2, promoting stromal proliferation, ECM deposition, and angiogenesis.
52. In contrast, myometrium contains a higher proportion of M1 (pro-inflammatory) macrophages, which produce TNF-α, IL-12, and IFN-γ, limiting fibrogenesis.
53. Data from scRNA-seq: A 2021 Nature Communications study identified ~30% of fibroid-infiltrating macrophages as M2-like, compared to <10% in myometrium, with M2 macrophages clustering near fibroid stromal cells.

- T-Cells:


54. Fibroids display reduced CD8+ cytotoxic T-cell infiltration and a higher CD4+/CD8+ ratio, suggesting impaired anti-tumor immunity.
55. Regulatory T-cells (Tregs, CD4+CD25+FOXP3+) are enriched in fibroids, suppressing immune surveillance via IL-10 and TGF-β secretion.
56. Th17 cells (IL-17A+) are also elevated in fibroids, contributing to inflammation and tissue remodeling through IL-17/IL-23 axis activation.
57. scRNA-seq insights: A 2022 Cell Reports Medicine study mapped 12 distinct T-cell clusters in fibroids, with Tregs and Th17 cells showing the most significant expansion compared to myometrium.

- Natural Killer (NK) Cells:


58. NK cells in fibroids exhibit reduced cytotoxic function, with downregulated perforin, granzyme B, and IFN-γ expression.
59. Fibroid-derived TGF-β and IL-10 impair NK cell activation, while PD-L1 upregulation on stromal cells induces NK cell exhaustion.
60. NK cell depletion studies: Mouse models demonstrate that NK cell deficiency accelerates fibroid growth, while adoptive transfer of activated NK cells reduces tumor volume by ~40%.

- Other Immune Cells:


61. Neutrophils: Elevated in fibroids, they release neutrophil extracellular traps (NETs) and elastase, which degrade ECM but also promote fibrosis via TGF-β activation.
62. Dendritic Cells (DCs): Fibroid-associated DCs exhibit reduced antigen-presenting capacity and secrete IL

    Uterine fibroids exemplify the convergence of molecular biology, genetics, and environmental influences in shaping women’s health outcomes. From the hyperactivity of estrogen receptors to the epigenetic silencing of tumor-suppressive genes, each layer of pathogenesis offers potential targets for intervention—whether through hormonal modulation, metabolic optimization, or immunomodulatory therapies. The field’s progress underscores the necessity of a multidisciplinary approach, integrating clinical observations with cutting-edge research to translate mechanistic insights into actionable strategies. As our understanding deepens, the future of fibroid management may lie not in symptomatic relief alone, but in precision-based solutions that disrupt the disease at its biological core, ultimately improving quality of life for millions affected globally.

FAQ

Why do uterine fibroids start growing in the first place?

The exact cause of fibroid growth isn’t fully understood, but they develop when smooth muscle cells in the uterus multiply abnormally, often influenced by estrogen and progesterone. Genetics, hormonal imbalances, and growth factors may also play a role. Fibroids tend to grow during reproductive years when estrogen levels are higher.

What are the main reasons women develop uterine fibroids?

Uterine fibroids are influenced by hormones like estrogen and progesterone, which stimulate their growth. Risk factors include family history, African ancestry, obesity, and exposure to early-life estrogen. Lifestyle and environmental factors may also contribute, though the precise causes remain unclear.

How do uterine fibroids cause heavy bleeding?

Fibroids can disrupt the uterine lining, leading to irregular or heavy menstrual bleeding (menorrhagia) by enlarging blood vessels or altering blood flow. Submucosal fibroids (near the uterine cavity) are most likely to cause bleeding, while intramural or subserosal fibroids may press on surrounding tissues.

Can uterine fibroids develop or grow after menopause, and what triggers it?

Fibroids can persist or rarely grow after menopause due to residual estrogen from fat tissue or other sources like adrenal glands. However, most shrink when estrogen drops significantly. Postmenopausal fibroids may cause symptoms like bleeding if they enlarge or irritate nearby structures.

What causes both uterine fibroids and polyps to form in the same woman?

Fibroids and polyps are distinct conditions, but both can stem from hormonal imbalances (especially estrogen dominance) and chronic inflammation in the uterus. Genetics, obesity, and age-related changes may increase the risk of developing either or both. They often require different treatments due to their different tissue structures.

Why do uterine fibroids sometimes flare up with symptoms like pain or bleeding?

Fibroid symptoms can worsen during hormonal shifts (e.g., menstruation, pregnancy, or perimenopause) when estrogen levels rise. Physical pressure from fibroid growth or changes in blood flow may also trigger flare-ups. Stress, poor circulation, or rapid growth phases can exacerbate discomfort.

• environmental-triggers
• fibroid-pathogenesis
• genetic-factors
• hormonal imbalances
• uterine fibroids